may be informative. For multifactorial disorders, the environmental factors that determine phenotype may also substantially differ between the Registry cases and contemporary test referral cases. The probability of a CNV in the unaffected population, P( | ) G D , should not include any patients with phenotypes associated with the disease, but it is not entirely clear that control groups described by Rosenfeld et al. 2 were all disease free. The following example, for illustrative purposes only, shows how the calculations by Rosenfeld et al.
2 might provide incorrect estimates of disease risk. Suppose that the 0.05 disease incidence consists of two types of disorders: type A, comprising 0.04 abnormal cases, are those with phenotypes that are unlikely to have a genetic disorder detectable by microarray and would not typically be referred for the test; and type B, which are the remaining 0.01 that are appropriate for microarray testing and match the referrals included by Rosenfeld et al. 2 Incidences of the CNVs in the affected and unaffected populations appropriate for testing are assumed to be as reported by Rosenfeld et al. 2 Results are presented for the distal 16p11.2 deletion and 15q11.2 deletion, which Rosenfeld et al.
2 report to have the highest and lowest risk for abnormality of the CNVs they evaluated. As can be seen from Table 1 , the net risk associated with the presence of the CNV is substantially lower under the A or B model. In fact, overall risk for abnormality if the 16p11.2 deletion is present is 28% or about five to six times the background (5%) risk, whereas overall risk if the 15q11.2 deletion is present is 6%, which is very close to the background (5%) risk. Both of these risks are substantially lower than those calculated by Rosenfeld et al. 2 The term "penetrance" is not appropriate because the probability calculated is for all abnormalities, not just those associated with the CNV.
Although the proposed Baysian approach to calculating the significance of a CNV for a broader set of disorders seems to be theoretically possible, I suggest that there is currently insufficient reliable data to generate the posterior risks. This is because the phenotype associated with each CNV is poorly defined and therefore the prior risk and prevalence of CNVs in appropriate populations are uncertain. Moreover, the diagnosis of disorders such as autism and schizophrenia is often imprecise and there may also be ascertainment bias in diagnosis, e.g., a patient who is initially considered to have an "uncertain" diagnosis is revised to "affected" following the detection of a CNV. Alternatively, a CNV is identified in a patient with an entirely unrelated disorder and it is assumed that the CNV is causal. This latter bias may explain why very high rates of CNVs associated with autism and neurocognitive alterations were reported in prenatal microarray studies performed because of fetal structural abnormalities identified by ultrasound; the ultrasound information was used to evaluate whether the CNV was likely to be clinically significant. Letters to the editor DNA tests and/or ultrasound and to provide reassurance following other screening. For many women, the presentation of a finding of a CNV of uncertain clinical significance may be very unhelpful. The challenge posed by using microarray testing needs to be met through enhanced professional education about the strengths and limitations of the testing, individualized counseling of women considering the test, and guidance on test utilization and interpretation from professional groups such as the American College of Medical Genetics and Genomics.
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where P (G | D) = probability of CNV given type B disease; P(D) = probability of type B disease = 0.01; (G | D) P = probability of CNV given no type B disease; P (D) = probability of no type B disease = 0.99.
Response to Benn
To the Editor: We thank Dr Benn for his letter titled "Prenatal Counseling and the Detection of Copy-Number Variants" 1 and agree that prenatal testing for copy-number variations (CNVs) differs from karyotyping, in which, more frequently, the patient can be given a clearer phenotypic expectation. Clarifying uncertainty is why we have attempted to estimate penetrance by including a wide range of possible associated disorders. 2 We also agree that prenatal microarray testing should be performed in the context of careful thought and counseling. Unclear results can be found regardless of careful use of the test, and our estimates provide one tool to aid counseling in such situations.
To obtain valid estimates for penetrance from CNV frequencies, it is important to know the fraction of the population with an abnormal phenotype that results in being referred for microarray testing. Our assumption that this fraction is approximately equal to the frequency of pediatric conditions with a genetic component-5% in a Canadian epidemiological study 3 -has some limitations, as pointed out by Dr Benn. Certain conditions may be diagnosed without microarray testing, although the rate of single-gene disorders in the Canadian study was only 0.36%.
3 Moreover, a subset of individuals with those conditions may still be referred for microarray testing, including individuals with conditions that can be caused by microdeletions (e.g., neurofibromatosis and cystic kidneys) or individuals who have atypical presentations of their diagnosed condition, for which clinicians wish to rule out other genetic factors altering the phenotype. Certain multifactorial conditions, if isolated, may not be a sufficient cause for microarray testing but are frequently part of syndromic presentations in individuals who are referred for microarray testing. Microarray testing may also be performed in a subset of individuals who have a condition, such as fetal alcohol syndrome, that does not have a genetic component, because it is important to rule out genetic causes before attributing their phenotypes to teratogens. Overall, although this raises the possibility that the 5% frequency may be an overestimate, further analysis of our data does not support Dr Benn's suggested reduction to 1%. For example, if we compare the population frequencies of known genetic syndromes such as Williams syndrome and Smith-Magenis syndrome due to microdeletions (1/7,500 4 and 0.9/15,000, 5 respectively) with the frequencies of these deletions in our patient population (110/48,637 and 46/48,637, respectively) , it suggests that our testing population comes from a 6% subset of the population with abnormal phenotypes. This may be considered an upper limit, given that we may be underascertaining these syndromes if some cases are diagnosed through other methods such as fluorescence in situ hybridization. Finally, as Dr Benn points out, factors contributing to disease have likely changed since the Canadian study. Some conditions, like autism, are on the rise and may help to counterbalance the subset of the 5% that are not being tested by microarray.
As we state in our original report, 2 the controls used are not known to be disease free, and this can cause underestimation of penetrance. If we recalculate penetrance assuming controls are completely unscreened (having a probability of disease (P(D)) of 0.0512), as described in the supplemental methods by Vassos et al., 6 the three CNVs with the highest penetrances have new estimates that are outside of their original confidence
